BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
January 25 2019 - 7:15AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in
developing innovative autologous cellular therapies for highly
debilitating neurodegenerative diseases, announced today that Chaim
Lebovits, CEO will provide a corporate overview presentation at the
NobleCon15 Investor Conference in Fort Lauderdale, Florida. Ralph
Kern M.D, MHSc, Chief Operating Officer and Chief Medical Officer
will also participate in a panel discussion focused on drug
development advances in neurodegenerative disease, including: (1)
unmet need, (2) patient selection, (3) enrichment strategies to
decrease heterogeneity and (4) practical use of biomarkers and
cognitive testing.
NobleCon15 is being held on Monday and Tuesday,
January 28-29, 2019 at the W Hotel in Fort Lauderdale, Florida.
Webcast will be available on Tuesday, January 29, 2019 on
BrainStorm's website www.brainstorm-cell.com, NobleCon15 website
www.nobleconference.com, and Channelchek portal
www.channelchek.com. Webcast will be archived for 90
days.
2019 NobleCon15 Conference Details: |
Date: |
Monday,
January 28, 2019 |
Presenter: |
Chaim
Lebovits, CEO |
Presentation Time: |
12:30 PM
Eastern Standard Time |
Location: |
Studio 2
at the W Hotel in Fort Lauderdale, Florida |
Webcast: |
https://goo.gl/LD9JLE |
Panelist: |
Ralph
Kern MD, MHSc, COO & CMO |
Panel Discussion: |
5:30 PM
Eastern Standard Time |
Location: |
Studio 1
at the W Hotel in Fort Lauderdale, Florida |
Meetings
BrainStorm senior management will also be
hosting institutional investor meetings at the 2019 NobleCon15
Conference. Please use the Investor contact information provided
below to schedule a meeting.
About NurOwn®NurOwn® (autologous MSC-NTF) cells
represent a promising investigational therapeutic approach to
targeting disease pathways important in neurodegenerative
disorders. MSC-NTF cells are produced from autologous, bone
marrow-derived mesenchymal stem cells (MSCs) that have been
expanded and differentiated ex vivo. MSCs are converted into
MSC-NTF cells by growing them under patented conditions that induce
the cells to secrete high levels of neurotrophic factors.
Autologous MSC-NTF cells can effectively deliver multiple NTFs and
immunomodulatory cytokines directly to the site of damage to elicit
a desired biological effect and ultimately slow or stabilize
disease progression. BrainStorm is currently conducting a Phase 3
pivotal trial of autologous MSC-NTF cells for the treatment of
amyotrophic lateral sclerosis (ALS). BrainStorm also recently
received U.S. FDA acceptance to initiate a Phase 2 open-label
multicenter trial in progressive Multiple Sclerosis (MS) and plans
to start enrollment in early 2019.
About BrainStorm Cell Therapeutics,
Inc. BrainStorm Cell Therapeutics Inc. is a
leading developer of innovative autologous adult stem cell
therapeutics for debilitating neurodegenerative diseases. The
Company holds the rights to clinical development and
commercialization of the NurOwn® technology platform used to
produce autologous MSC-NTF cells through an exclusive, worldwide
licensing agreement. Autologous MSC-NTF cells have received Orphan
Drug status designation from the U.S. Food and Drug Administration
(U.S. FDA) and the European Medicines Agency (EMA) in ALS.
BrainStorm is currently enrolling a Phase 3 pivotal trial in ALS
(NCT03280056), investigating repeat-administration of autologous
MSC-NTF cells at six sites in the U.S., supported by a grant from
the California Institute for Regenerative Medicine (CIRM
CLIN2-0989). The pivotal study is intended to support a filing for
U.S. FDA approval of autologous MSC-NTF cells in ALS. For more
information, visit BrainStorm's website at
www.brainstorm-cell.com.
About Noble Capital Markets, Inc.Noble Capital
Markets is an equity-research driven, full-service, investment
& merchant banking boutique focused on emerging growth
companies. In addition to NobleCon, Noble hosts numerous “non-deal”
corporate road shows across the United States and Canada. In late
2018, Noble launched Channelchek.com which features advanced market
data, institutional-quality research, balanced news, videos and
podcasts covering more than 6,000 emerging growth companies.
Members: FINRA, SIPC, MSRB. www.noblecapitalmarkets.com.
Safe-Harbor Statements
Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
CONTACTS
Media:Joseph PetrozielloBrainStorm Cell TherapeuticsPhone:
+1.215.485.6797Email: JP@brainstorm-cell.com
Investors:Marcy Beth NanusSolebury TroutPhone:
+1.646.378.2927Email: MNanus@troutgroup.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024